×
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
OTCMKTS:PHGUF

Pharming Group (PHGUF) Stock Forecast, Price & News

$0.85
+0.03 (+3.05%)
(As of 05/26/2022 01:24 PM ET)
Add
Compare
Today's Range
$0.85
$0.85
50-Day Range
$0.75
$0.95
52-Week Range
$0.74
$1.26
Volume
2,000 shs
Average Volume
5,127 shs
Market Capitalization
$528.87 million
P/E Ratio
42.27
Dividend Yield
N/A
Beta
1.62
30 days | 90 days | 365 days | Advanced Chart
Receive PHGUF News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter.

Pharming Group logo

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Tobacco products
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:PHGUF
CIK
N/A
Employees
277
Year Founded
N/A

Sales & Book Value

Annual Sales
$198.87 million
Cash Flow
$0.06 per share
Book Value
$0.31 per share

Profitability

Net Income
$16 million
Pretax Margin
11.60%

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$528.87 million
Optionable
Not Optionable

Company Calendar

Last Earnings
3/05/2015
Today
5/27/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.87 out of 5 stars

Analyst Opinion: 3.5Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -













Pharming Group (OTCMKTS:PHGUF) Frequently Asked Questions

Is Pharming Group a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pharming Group in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Pharming Group stock.
View analyst ratings for Pharming Group
or view top-rated stocks.

Are investors shorting Pharming Group?

Pharming Group saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 1,525,800 shares, an increase of 31.7% from the April 15th total of 1,158,400 shares. Based on an average trading volume of 400 shares, the days-to-cover ratio is currently 3,814.5 days.
View Pharming Group's Short Interest
.

How were Pharming Group's earnings last quarter?

Pharming Group (OTCMKTS:PHGUF) issued its earnings results on Thursday, March, 5th. The biotechnology company reported $0.05 earnings per share for the quarter, beating analysts' consensus estimates of $0.04 by $0.01. Pharming Group had a trailing twelve-month return on equity of 8.30% and a net margin of 8.04%.
View Pharming Group's earnings history
.

What price target have analysts set for PHGUF?

1 analysts have issued 1 year price objectives for Pharming Group's stock. Their forecasts range from $3.10 to $3.10. On average, they anticipate Pharming Group's share price to reach $3.10 in the next twelve months. This suggests a possible upside of 266.9% from the stock's current price.
View analysts' price targets for Pharming Group
or view top-rated stocks among Wall Street analysts.

Who are Pharming Group's key executives?
Pharming Group's management team includes the following people:
  • Dr. Sijmen de Vries M.B.A., M.D., MBA, Pres, CEO & Exec. Director (Age 63, Pay $1.1M)
  • Dr. Bruno M. L. Giannetti, Consultant (Age 70, Pay $659.18k)
  • Mr. Jeroen Wakkerman, Chief Financial Officer (Age 53)
  • Ms. Mireille Sanders M.Sc., Chief Operations Officer (Age 54)
  • Dr. Robert Friesen Ph.D., Chief Scientific Officer (Age 58)
  • Susanne Embleton, Investor Relations Mang.
  • Mr. Ruud Van Outersterp, Chief Ethics & Compliance Officer (Age 58)
  • Mr. Anurag Relan, Chief Medical Officer (Age 50)
  • Mr. Paul Th. Jansse, VP & Head of Non-US Commercial Operations (Age 53)
  • Mr. Stephen Toor, Chief Commercial Officer & GM of Americas (Age 51)
Who are some of Pharming Group's key competitors?
What is Pharming Group's stock symbol?

Pharming Group trades on the OTCMKTS under the ticker symbol "PHGUF."

How do I buy shares of Pharming Group?

Shares of PHGUF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pharming Group's stock price today?

One share of PHGUF stock can currently be purchased for approximately $0.85.

How much money does Pharming Group make?

Pharming Group has a market capitalization of $528.87 million and generates $198.87 million in revenue each year. The biotechnology company earns $16 million in net income (profit) each year or $0.019990 on an earnings per share basis.

How many employees does Pharming Group have?

Pharming Group employs 277 workers across the globe.

What is Pharming Group's official website?

The official website for Pharming Group is www.pharming.com.

How can I contact Pharming Group?

Pharming Group's mailing address is Darwinweg 24, Leiden P7, 2333 CR. The biotechnology company can be reached via phone at (171) 524-7400, via email at [email protected], or via fax at 31-0-71-524-7445.

This page was last updated on 5/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.